These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 24077982)

  • 21. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study.
    Amorim S; Stathis A; Gleeson M; Iyengar S; Magarotto V; Leleu X; Morschhauser F; Karlin L; Broussais F; Rezai K; Herait P; Kahatt C; Lokiec F; Salles G; Facon T; Palumbo A; Cunningham D; Zucca E; Thieblemont C
    Lancet Haematol; 2016 Apr; 3(4):e196-204. PubMed ID: 27063978
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer.
    Infante JR; Patnaik A; Verschraegen CF; Olszanski AJ; Shaheen M; Burris HA; Tolcher AW; Papadopoulos KP; Beeram M; Hynes SM; Leohr J; Lin AB; Li LQ; McGlothlin A; Farrington DL; Westin EH; Cohen RB
    Cancer Chemother Pharmacol; 2017 Feb; 79(2):315-326. PubMed ID: 28097385
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study.
    Gazzah A; Bedard PL; Hierro C; Kang YK; Abdul Razak A; Ryu MH; Demers B; Fagniez N; Henry C; Hospitel M; Soria JC; Tabernero J
    Ann Oncol; 2022 Apr; 33(4):416-425. PubMed ID: 35026412
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors.
    Weiss GJ; Jameson G; Von Hoff DD; Valsasina B; Davite C; Di Giulio C; Fiorentini F; Alzani R; Carpinelli P; Di Sanzo A; Galvani A; Isacchi A; Ramanathan RK
    Invest New Drugs; 2018 Feb; 36(1):85-95. PubMed ID: 28726132
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors.
    Dees EC; Infante JR; Cohen RB; O'Neil BH; Jones S; von Mehren M; Danaee H; Lee Y; Ecsedy J; Manfredi M; Galvin K; Stringer B; Liu H; Eton O; Fingert H; Burris H
    Cancer Chemother Pharmacol; 2011 Apr; 67(4):945-54. PubMed ID: 20607239
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.
    Tamura K; Nakagawa K; Kurata T; Satoh T; Nogami T; Takeda K; Mitsuoka S; Yoshimura N; Kudoh S; Negoro S; Fukuoka M
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):285-93. PubMed ID: 17136542
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer-results of a first-in-man dose-escalation study with a fixed-dose extension phase.
    Isambert N; Delord JP; Soria JC; Hollebecque A; Gomez-Roca C; Purcea D; Rouits E; Belli R; Fumoleau P
    Ann Oncol; 2015 May; 26(5):1005-1011. PubMed ID: 25646368
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Phase I Dose-Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low-Grade or Intermediate-Grade B-Cell or T-Cell Lymphoma.
    Foss FM; Parker T
    Oncologist; 2018 Apr; 23(4):397-e30. PubMed ID: 29438091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer.
    Flaherty KT; Lorusso PM; Demichele A; Abramson VG; Courtney R; Randolph SS; Shaik MN; Wilner KD; O'Dwyer PJ; Schwartz GK
    Clin Cancer Res; 2012 Jan; 18(2):568-76. PubMed ID: 22090362
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors.
    Shimizu T; LoRusso PM; Papadopoulos KP; Patnaik A; Beeram M; Smith LS; Rasco DW; Mays TA; Chambers G; Ma A; Wang J; Laliberte R; Voi M; Tolcher AW
    Clin Cancer Res; 2014 Oct; 20(19):5032-40. PubMed ID: 25107918
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
    Li S; Huang H; Liao H; Zhan J; Guo Y; Zou BY; Jiang WQ; Guan ZZ; Yang XQ
    Int J Clin Pharmacol Ther; 2013 Feb; 51(2):96-105. PubMed ID: 23127487
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase 1 study of APTO-253 HCl, an inducer of KLF4, in patients with advanced or metastatic solid tumors.
    Cercek A; Wheler J; Murray PE; Zhou S; Saltz L
    Invest New Drugs; 2015 Oct; 33(5):1086-92. PubMed ID: 26268924
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial.
    Papadopoulos KP; Ben-Ami E; Patnaik A; Trone D; Li J; Demetri GD
    BMC Cancer; 2018 Aug; 18(1):790. PubMed ID: 30081867
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors.
    Oh DY; Lee SH; Han SW; Kim MJ; Kim TM; Kim TY; Heo DS; Yuasa M; Yanagihara Y; Bang YJ
    Cancer Res Treat; 2015 Oct; 47(4):607-15. PubMed ID: 25715763
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas.
    Aghajanian C; Burris HA; Jones S; Spriggs DR; Cohen MB; Peck R; Sabbatini P; Hensley ML; Greco FA; Dupont J; O'Connor OA
    J Clin Oncol; 2007 Mar; 25(9):1082-8. PubMed ID: 17261851
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Phase I trial of the kinesin spindle protein (Eg5) inhibitor AZD4877 in patients with solid and lymphoid malignancies.
    Gerecitano JF; Stephenson JJ; Lewis NL; Osmukhina A; Li J; Wu K; You Z; Huszar D; Skolnik JM; Schwartz GK
    Invest New Drugs; 2013 Apr; 31(2):355-62. PubMed ID: 22615058
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours.
    Ameratunga M; Braña I; Bono P; Postel-Vinay S; Plummer R; Aspegren J; Korjamo T; Snapir A; de Bono JS
    Br J Cancer; 2020 Dec; 123(12):1730-1736. PubMed ID: 32989226
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors.
    Cohen RB; Jones SF; Aggarwal C; von Mehren M; Cheng J; Spigel DR; Greco FA; Mariani M; Rocchetti M; Ceruti R; Comis S; Laffranchi B; Moll J; Burris HA
    Clin Cancer Res; 2009 Nov; 15(21):6694-701. PubMed ID: 19825950
    [TBL] [Abstract][Full Text] [Related]  

  • 39. First-in-man phase I study assessing the safety and pharmacokinetics of a 1-hour intravenous infusion of the doxorubicin prodrug DTS-201 every 3 weeks in patients with advanced or metastatic solid tumours.
    Schöffski P; Delord JP; Brain E; Robert J; Dumez H; Gasmi J; Trouet A
    Eur J Cancer; 2017 Nov; 86():240-247. PubMed ID: 29055839
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma.
    Choy E; Flamand Y; Balasubramanian S; Butrynski JE; Harmon DC; George S; Cote GM; Wagner AJ; Morgan JA; Sirisawad M; Mani C; Hornicek FJ; Duan Z; Demetri GD
    Cancer; 2015 Apr; 121(8):1223-30. PubMed ID: 25536954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.